Evidence map›Paper›PMID 28270859›Full record

ArticleInfectious agents and cancer2017

Genetic variability in E6, E7 and L1 genes of Human Papillomavirus 62 and its prevalence in Mexico.

Cristina Artaza-Irigaray, María Guadalupe Flores-Miramontes, Dominik Olszewski, María Teresa Magaña-Torres, María Guadalupe López-Cardona, Yelda Aurora Leal-Herrera, Patricia Piña-Sánchez, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy

Open access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. E6/E7 and E6Frontiers in immunology · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Cristina Artaza-IrigarayDivisión de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco Mexico.
María Guadalupe Flores-MiramontesDivisión de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco Mexico.
Dominik OlszewskiInstitute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany.
María Teresa Magaña-TorresDivisión de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco Mexico.
María Guadalupe López-CardonaUnidad de Medicina Genómica y Genética, Hospital Regional Dr. Valentín Gómez Farías - ISSSTE, Guadalajara, Jalisco Mexico.
Yelda Aurora Leal-HerreraUnidad de Investigación Médica Yucatán (UIMY) - IMSS, Mérida, Yucatán Mexico.
Patricia Piña-SánchezLaboratorio de Oncología Molecular, Unidad de Investigación Médica en Enfermedades Oncológicas (UIMEO) - IMSS, Ciudad de Mexico, Mexico.
Luis Felipe Jave-Suárez *División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco Mexico.
Adriana Aguilar-Lemarroy *División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco Mexico.ORCID 0000-0001-9288-4824
Mexican Social Security Institute · MXHeidelberg University · DEInstitute for Social Security and Services for State Workers · MXSecretaría de Investigación, Innovación y Educación Superior · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) is the main etiological agent of cervical cancer, the third most common cancer among women globally and the second most frequent in Mexico. Persistent infection with high-risk HPV genotypes is associated with premalignant lesions and cervical cancer development. HPVs considered as low risk or not yet classified, are often found in coinfection with different HPV genotypes. Indeed, HPV62 is one of the most prevalent HPV detected in some countries, but there is limited information about its prevalence in other regions and there are no HPV62 variants currently described. The aim of this study was to determine the prevalence of HPV62 in cervical samples from Mexican women and to identify mutations in the L1, E6 and E7 genes, which have never been reported in our population.

methodsHPV screening was performed by Cobas HPV Test in women who attended prevention health programs and dysplasia clinics. All HPV positive samples (

resultsUsing Linear Array, HPV62 prevalence was 7.6% in general population, 8% in Cervical Intraepithelial Neoplasia grade 1 (CIN1) samples and 4.6% in cervical samples. The presence of HPV62 was confirmed with Next-Generation sequencing. Regarding L1 gene, novel sequence variations were detected, but they did not alter the tertiary structure of the protein. Moreover, several nucleotide substitutions were found in E6 and E7 genes compared to reference HPV62 genomic sequence. Specifically, three non-synonymous sequence variations were detected, two in E6 and one in E7.

conclusionsHPV62 is a frequent HPV genotype found mainly in general population and in women with CIN1, and in 90.5% of the cases it was found in coinfection with other HPVs. Novel nucleotide changes in its

Indexed as

Cervical cancerE6E7HPV62L1

Identifiers

PMID28270859
PMCPMC5336664
OpenAlexW2592440313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.